Cargando…
New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma
Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at JADPRO Live Virtual 2021, presenters compared pivotal trials in...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126344/ https://www.ncbi.nlm.nih.gov/pubmed/35663181 http://dx.doi.org/10.6004/jadpro.2022.13.3.30 |